George Medicines
George Medicines is a late-stage biopharmaceutical company dedicated to developing innovative, single-pill, multi-mechanism treatments for cardiometabolic diseases such as hypertension and diabetes. The company aims to improve clinical outcomes, safety, and therapy adherence by combining existing medicines into proprietary low-dose formulations. It is a spin-out from The George Institute for Global Health and is backed by George Health and Brandon Capital. The company's pipeline includes GMRx2, in Phase III for hypertension, and GMRx4, in Phase II for type 2 diabetes, among other research programs. The company is also actively involved in clinical trials and research collaborations to address the global burden of non-communicable diseases.
Industries
Nr. of Employees
small (1-50)
Products
Oral fixed‑dose triple antihypertensive combination (angiotensin receptor blocker + calcium channel blocker + thiazide‑like diuretic)
Fixed‑dose oral tablet combining three antihypertensive agent classes in multiple dose strengths (low/ultra‑low and standard) developed for initial and maintenance treatment of hypertension.
Oral fixed‑dose triple antihypertensive combination (angiotensin receptor blocker + calcium channel blocker + thiazide‑like diuretic)
Fixed‑dose oral tablet combining three antihypertensive agent classes in multiple dose strengths (low/ultra‑low and standard) developed for initial and maintenance treatment of hypertension.
Services
End‑to‑end development support for late‑stage fixed‑dose combination medicines including clinical program design, multinational trial execution and regulatory filing support.
Collaborative development with external formulation experts and contract manufacturers to create and supply fixed‑dose combination tablet formulations.
Operational delivery of randomized, controlled Phase II and Phase III trials across multiple countries using CROs and academic site networks, including decentralized trial components.
Preparation and submission of regulatory dossiers and coordination of interactions with regulatory authorities to support marketing authorisation.
Structuring and negotiating licensing, supply and commercialization agreements for developed medicines across territories.
Support for investigator‑led trials including provision of study drug, operational collaboration and coordination with academic partners for large‑scale pragmatic studies.
End‑to‑end development support for late‑stage fixed‑dose combination medicines including clinical program design, multinational trial execution and regulatory filing support.
Collaborative development with external formulation experts and contract manufacturers to create and supply fixed‑dose combination tablet formulations.
Operational delivery of randomized, controlled Phase II and Phase III trials across multiple countries using CROs and academic site networks, including decentralized trial components.
Preparation and submission of regulatory dossiers and coordination of interactions with regulatory authorities to support marketing authorisation.
Structuring and negotiating licensing, supply and commercialization agreements for developed medicines across territories.
Support for investigator‑led trials including provision of study drug, operational collaboration and coordination with academic partners for large‑scale pragmatic studies.
Expertise Areas
- Clinical trial management (Phase II–III)
- Fixed‑dose combination formulation and dose strategy
- Regulatory affairs and dossier preparation (IND/NDA)
- Commercialisation and licensing strategies
Key Technologies
- Fixed‑dose single‑pill combination formulation
- Ultra‑low‑dose formulation strategies
- Home blood pressure monitoring endpoints
- Medical IoT and remote vital‑sign capture
News & Updates
Results from two Phase III trials of GMRx2, a multi-mechanism triple combination therapy, showed significant blood pressure reduction and improved control rates versus dual therapy or placebo, with good tolerability. The trials also included a study in Africa demonstrating over 80% BP control from 1 month to end of follow-up.
Results from two Phase III trials of GMRx2, a multi-mechanism triple combination therapy, showed significant blood pressure reduction and improved control rates versus dual therapy or placebo, with good tolerability. The trials also included a study in Africa demonstrating over 80% BP control from 1 month to end of follow-up.